IPO Year: 2021
Exchange: NASDAQ
Date | Price Target | Rating | Analyst |
---|
DENVER, Sept. 25, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the enrollment of four additional subjects in a 10-day period in its pivotal NEUTRALIZE-AKI trial, bringing total trial enrollment to 46. This trial is evaluating the safety and efficacy of SeaStar Medical's proprietary therapeutic Selective Cytopheretic Device (SCD) in adults with acute kidney injury (AKI) in the intensive care unit (ICU) receiving continuous kidney replacement therapy (CKRT). "We are encouraged to see a recent uptick in enrollmen
DENVER, Sept. 05, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference on Wednesday, September 11, 2024 at 9:00 a.m. Eastern time. A webcast of the fireside chat will be available on the Events and Presentations section of the Company's website. Management is available for in-person and virtual one-on-one meetings throughout the conference being held September 9-11. Institutional investors and industry pro
DENVER, Sept. 04, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU) (SeaStar Medical), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports that it has now retired all long-term debt, which will be reflected on its balance sheet for the quarter ending September 30, 2024. "At the end of 2023, we reported more than $9 million in convertible notes and long-term interest bearing debt. As of today, we have eliminated this debt," said Eric Schlorff, SeaStar Medical CEO. "SeaStar Medical is in the strongest financial position since becoming a public company nearly two year
DENVER, Aug. 13, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU) ("SeaStar Medical" or the "Company"), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the three and six months ended June 30, 2024 and provides a business update. "Our recent commercial, clinical and corporate achievements have significantly strengthened our company and support an active and exciting future," said Eric Schlorff, SeaStar Medical CEO. "Foremost were our initial commercial sales of QUELIMMUNE™, which has already been used to provide potentially life-saving therapy t
MINNEAPOLIS, July 26, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company dedicated to transforming the lives of patients suffering from fluid overload, today announced that the first patient has been treated with the newly launched QUELIMMUNE™ therapy in a commercial setting at Cincinnati Children's. QUELIMMUNE, manufactured for SeaStar Medical (NASDAQ:ICU) and exclusively licensed and distributed in U.S. pediatric hospitals by Nuwellis, is a novel therapy designed to treat pediatric patients (weighing 10 kg or more) suffering from acute kidney injury (AKI) with sepsis or a septic condition and requiring kidney replacement therapy (KRT). Dr. Stuart Goldste
DENVER, July 23, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU) (SeaStar Medical) reports treatment of the first patient in a commercial setting with QUELIMMUNE™, its U.S. Food and Drug Administration (FDA)-approved, patented cell-directed extracorporeal therapy to treat acute kidney injury (AKI) in pediatric patients weighing 10 kilograms or greater with sepsis or a septic condition requiring kidney replacement therapy (KRT). With this development, the Company has now met the August 20, 2024 FDA deadline to begin patient treatments, which is designated in the FDA's approval of QUELIMMUNE. "This commercial milestone is highly gratifying to the SeaStar Medical te
MINNEAPOLIS, July 17, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company dedicated to transforming the lives of patients suffering from fluid overload, is proud to announce its first commercial sale of QUELIMMUNE™, a novel therapy developed by SeaStar Medical Holding Corporation for pediatric patients suffering from an uncontrolled inflammatory response triggered by their immune systems, to Cincinnati Children's. We believe this milestone marks a significant advancement in pediatric critical care and underscores Nuwellis' commitment to revolutionizing pediatric patient outcomes. QUELIMMUNE, or Selective Cytopheretic Device for pediatrics, represents a tran
Reimbursement expected to accelerate medical site activations and cover a portion of the Company's NEUTRALIZE-AKI trial costs DENVER, July 16, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces receipt of a Category B Coverage Letter from the U.S. Centers for Medicare & Medicaid Services (CMS) for the NEUTRALIZE-AKI pivotal trial evaluating the Company's Selective Cytopheretic Device (SCD) in adults with acute kidney injury (AKI). CMS will pay for certain expenses incurred by medical centers treating patients covered
DENVER, July 12, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU) (SeaStar Medical) reports the initial commercial sale of QUELIMMUNE™-Pediatric to its U.S. license and distribution partner, Nuwellis, Inc. QUELIMMUNE is SeaStar Medical's Selective Cytopheretic Device-Pediatric (SCD-PED), a patented cell-directed extracorporeal therapy that selectively targets the most highly activated neutrophils and monocytes responsible for hyperactive immune response. QUELIMMUNE is approved by the U.S. Food and Drug Administration (FDA) as a Humanitarian Use Device (HUD) under a Humanitarian Device Exemption (HDE) to treat pediatric acute kidney injury (AKI) in patients weighing
DENVER, July 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU) (SeaStar Medical) announces that it has closed its previously announced registered offering for the issuance and sale of an aggregate of 947,868 shares of its common stock at a purchase price of $10.55 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, SeaStar Medical has issued in a concurrent private placement unregistered warrants to purchase up to 947,868 shares of common stock. The warrants have an exercise price of $10.55 per share, are immediately exercisable and will expire five years following the issuance date. H.C. Wainwright &
EFFECT - SeaStar Medical Holding Corp (0001831868) (Filer)
EFFECT - SeaStar Medical Holding Corp (0001831868) (Filer)
S-3/A - SeaStar Medical Holding Corp (0001831868) (Filer)
S-3/A - SeaStar Medical Holding Corp (0001831868) (Filer)
8-K - SeaStar Medical Holding Corp (0001831868) (Filer)
10-Q - SeaStar Medical Holding Corp (0001831868) (Filer)
S-3 - SeaStar Medical Holding Corp (0001831868) (Filer)
D - SeaStar Medical Holding Corp (0001831868) (Filer)
8-K - SeaStar Medical Holding Corp (0001831868) (Filer)
424B5 - SeaStar Medical Holding Corp (0001831868) (Filer)
4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
SeaStar Medical Holding Corporation (NASDAQ:ICU) (SeaStar Medical) reports treatment of the first patient in a commercial setting with QUELIMMUNE™, its U.S. Food and Drug Administration (FDA)-approved, patented cell-directed extracorporeal therapy to treat acute kidney injury (AKI) in pediatric patients weighing 10 kilograms or greater with sepsis or a septic condition requiring kidney replacement therapy (KRT). With this development, the Company has now met the August 20, 2024 FDA deadline to begin patient treatments, which is designated in the FDA's approval of QUELIMMUNE.
Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company dedicated to transforming the lives of patients suffering from fluid overload, is proud to announce its first commercial sale of QUELIMMUNE™, a novel therapy developed by SeaStar Medical Holding Corporation for pediatric patients suffering from an uncontrolled inflammatory response triggered by their immune systems, to Cincinnati Children's. We believe this milestone marks a significant advancement in pediatric critical care and underscores Nuwellis' commitment to revolutionizing pediatric patient outcomes. QUELIMMUNE, or Selective Cytopheretic Device for pediatrics, represents a transformative solution for pediatric patients sufferi
Reimbursement expected to accelerate medical site activations and cover a portion of the Company's NEUTRALIZE-AKI trial costsDENVER, July 16, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces receipt of a Category B Coverage Letter from the U.S. Centers for Medicare & Medicaid Services (CMS) for the NEUTRALIZE-AKI pivotal trial evaluating the Company's Selective Cytopheretic Device (SCD) in adults with acute kidney injury (AKI). CMS will pay for certain expenses incurred by medical centers treating patients covered by M
SeaStar Medical Holding's (NYSE:ICU) short percent of float has risen 97.61% since its last report. The company recently reported that it has 231 thousand shares sold short, which is 8.26% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 1% on Wednesday. The Dow traded up 0.50% to 39,488.59 while the NASDAQ rose 1.01% to 18,615.28. The S&P 500 also rose, gaining, 0.70% to 5,616.11. Check This Out: Nvidia, Amazon And 2 Other Stocks Insiders Are Selling Leading and Lagging SectorsMaterials shares jumped by 1.2% on Wednesday. In trading on Wednesday, financials shares fell by 0.1%. Top Headline The EIA said U.S. crude oil inventories declined by 3.444 million barrels in the week ended July 5, compared to market estimates of a 3.0 million decline. Equities Trading UP Virpax Pharmaceuticals
Shares of SeaStar Medical Holding Corporation (NASDAQ:ICU) fell sharply during Wednesday's session after the company entered into a $10 million registered direct offering of 947,868 shares at $10.55 per share. SeaStar Medical shares dipped 34% to $8.55 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) shares jumped 139% to $2.78 after the company announced results for a Swine Model pilot study for Probudur. Kazia Therapeutics Limited (NASDAQ:KZIA) gained 129% to $0.4325 after the company announced results from GBM-AGILE, a phase II/III study that included an evaluation of paxalisib versus standard of
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 50 points on Wednesday. The Dow traded up 0.10% to 39,329.75 while the NASDAQ rose 0.34% to 18,491.35. The S&P 500 also rose, gaining, 0.24% to 5,590.26. Check This Out: Nvidia, Amazon And 2 Other Stocks Insiders Are Selling Leading and Lagging SectorsMaterials shares jumped by 0.7% on Wednesday. In trading on Wednesday, consumer discretionary shares fell by 0.2%. Top Headline The EIA said U.S. crude oil inventories declined by 3.444 million barrels in the week ended July 5, compared to market estimates of a 3.0 million decline. Equities Trading UP Vir
U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 100 points on Wednesday. The Dow traded up 0.02% to 39,298.72 while the NASDAQ rose 0.53% to 18,526.10. The S&P 500 also rose, gaining, 0.28% to 5,592.62. Check This Out: Nvidia, Amazon And 2 Other Stocks Insiders Are Selling Leading and Lagging SectorsInformation technology shares jumped by 0.7% on Wednesday. In trading on Wednesday, financials shares fell by 0.3%. Top Headline Shares of Manchester United plc (NYSE:MANU) gained around 4% on Wednesday after the company reported results for the third quarter. The company reported quarterly loss of 31 cents per share which missed the a
Restatement of non-cash items is not expected to materially impact cash position or operations DENVER, March 27, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that it will restate its financial statements for the fiscal year ended December 31, 2022 and for the interim periods ended March 31, 2023, June 30, 2023 and September 30, 2023. The restatement will impact the accounting treatment and classification of certain outstanding warrants and the prepaid forward purchase arrangement that was terminated in
Company plans to hold a business update conference call in April DENVER, March 12, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, provides updates on the acute kidney injury (AKI) programs it is developing with its patented, first-to-market, cell-directed Selective Cytopheretic Device (SCD) extracorporeal therapy in critically ill patients with AKI. "We now have 21 subjects enrolled across five clinical sites in our NEUTRALIZE-AKI pivotal clinical trial, which is intended to evaluate the safety and efficacy of our
DENVER, Nov. 14, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU) ("SeaStar Medical" or the "Company"), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the three and nine months ended September 30, 2023 and provides a business update. "Recent clinical and regulatory successes have significantly improved and strengthened our company's prospects," said Eric Schlorff, SeaStar Medical CEO. "We are addressing the remaining administrative steps outlined by the U.S. Food and Drug Administration (FDA) for approval of the Selective Cytopheretic Device Pediatric (SCD-P
DENVER, Aug. 22, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU) ("SeaStar Medical" or the "Company"), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will hold a business update conference call today at 4:00 p.m. Eastern time (1:00 p.m. Pacific time). During the call, management will provide a clinical and regulatory update and review the Company's value proposition, including the commercial opportunity. A slide presentation to accompany management's prepared remarks will be available on the webcast and on the Events and Presentations page of the Investors
Management to hold a business update conference call on August 22 beginning at 4:00 p.m. Eastern time DENVER, Aug. 14, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU) ("SeaStar Medical" or the "Company"), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the three and six months ended June 30, 2023 and provides a business update. "With the recent activation of a second clinical site, we now have two medical centers open for enrolling patients in our pivotal trial evaluating the safety and efficacy of our patented, first-in-class, cell-directed Selective Cyt
DENVER, May 15, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU) ("SeaStar Medical" or the "Company"), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the three months ended March 31, 2023 and provides a business update. "Enrollment of the first patient in our pivotal NEUTRALIZE-AKI trial and activation of additional clinical trial sites are expected in the coming weeks. This trial is evaluating the safety and efficacy of our patented, first-in-class, cell-directed Selective Cytopheretic Device (SCD) extracorporeal therapy in critically ill adults with acut
DENVER, March 30, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU) ("SeaStar Medical" or the "Company"), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, provides a business update and reports financial results for the year ended December 31, 2022. "We are focusing on executing near-term milestones that will advance our business," said Eric Schlorff, SeaStar Medical CEO. "Our immediate efforts are aimed at raising awareness with the medical community of our cell-directed extracorporeal therapy's potential for playing a life-saving role for critically ill patients, working with regulators to
DENVER, Feb. 14, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical (NASDAQ:ICU), a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces it will hold a conference call to discuss business updates including the recent FDA approval to conduct a pivotal trial evaluating the effectiveness of its Selective Cytopheretic Device (SCD) in reducing hyperinflammation in adults with acute kidney injury (AKI) and an update regarding the Humanitarian Device Exemption (HDE) submission for market approval for use of the SCD for critically ill children with AKI. Date/Time:Wednesday, February 15, 4:00 p.m. ET / 1:00 p.m. PT Pre-Regis
4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
4/A - SeaStar Medical Holding Corp (0001831868) (Issuer)
3 - SeaStar Medical Holding Corp (0001831868) (Issuer)
4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
4 - SeaStar Medical Holding Corp (0001831868) (Issuer)